Examiner Cite

Initial* No

Patent Number

Kind

publisher, city and/or country where published.

Code¹ Issue Date

Remove

Remove

Τ۶

Pages,Columns,Lines where

Relevant Passages or Relevant

	Application Number		10591954		
	Filing Date		2006-09-08		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor	KAUF	PPINEN Esko I. et al.		
	Art Unit				
	Examiner Name				
	Attorney Docket Numb	or	3505-1027		

U.S. PATENTS

Name of Patentee or Applicant

of cited Document

								ı ıguı	оо тфроот	
	1									
If you wis	h to ad	ld additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Rele	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear	
	1									
If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TA
	1									
If you wis	h to ad	d additional Foreign P	atent Do	cument	citation	information of	lease click the Add	hutto	n Add	

NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s),

Examiner Cite

Initials* No

Application Number 10591954 Filing Date 2006-09-08 INFORMATION DISCLOSURE First Named Inventor KAUPPINEN Esko Let al. STATEMENT BY APPLICANT Art Unit (Not for submission under 37 CFR 1.99) Evaminor Namo Attorney Docket Number 3505-1027

1 GLERUP, Marianna et al.; "Synthesis of Multi-walled Carbon Nanohubes and Nano-fibres Using the Aerosol Methorith Metal-ions as the Catalyst Precursors," Chemical Physics Letters, 2003, Vol. 377, pp. 293-298	d
VANDER WAL, Randall L. et al.; "Comparative Flame and Furnace Synthesis of Single-waited Cerbon Nanotubes Chemical Physics Letters, 9 May 2001, Vol. 336, pp. 24-32.	-
3 Japanese Office Action, dated July 13, 2011, in Application No. 2007-582357.	
If you wish to add additional non-patent literature document citation information please click the Add button Add	
EXAMINER SIGNATURE	
Examiner Signature Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a 1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

English language translation is attached.

| INFORMATION DISCLOSURE | Filing Date | 2006.99.08 | Fix Named Inventor | KALIFPRIEN Eako 1. et al | Art Unit | Art Unit | Examiner Name | Ex

Attorney Docket Number 3

3505-1027

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart toreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Places see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Benoit Castel/	Date (YYYY-MM-DD)	2011-09-19
Name/Print	BENOIT CASTEL	Registration Number	35.041

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.